Genprex (GNPX) Announces $25 Million Registered Direct Offering of Common Stock

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced it has entered into securities purchase agreements with two healthcare-dedicated institutional investors for the purchase and sale of 4,000,000 shares of its common stock at a purchase price of $6.25 per share in a registered direct offering priced at-the-market under Nasdaq rules. No warrants will be issued in connection with the transaction. The closing of the offering is expected to occur on or about February 11, 2021, subject to the satisfaction of customary closing conditions.

A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.

You May Also Be Interested In

• Genprex signs CDMO deal to scale up diabetes gene therapy output
• Entera Bio Ltd. (ENTX) files for 134.8M share offering by selling stockholders
• Singularity Future Technology closes $5M registered direct offering